11.3.1 Overview 11.3.2 Financial Performance 11.3.3 Product Outlook 11.3.4 Key Developments 11.4 ASTRAZENECA PLC 11.4.1 Overview 11.4.2 Financial Performance 11.4.3 Product Outlook 11.4.4 Key Developments 11.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 11.5.1 Overview 11.5.2 Financial Performance 11.5.3 Product Outlook 11.5.4 Key Developments 11.6 MERCK & CO
In the months that followed, a number of human studies were started, many of which are still under way
To apply the technique from bench to clinic, there are still some challenges that should be addressed
Liquid forms are often chosen for convenience and faster absorption, particularly around workouts
If you want the broader medication class context, GLP-1 Receptor Agonists explains how incretin-based medicines fit into diabetes and weight-management care
Research in people with Type 2 diabetes has shown that GLP-1 receptor agonists may lower the chances of having a heart attack, stroke, or dying from cardiovascular (heart and blood vessel) problems
